AgomAb Therapeutics NV
Statements
Cash Flow
AgomAb Therapeutics NV (AGMB) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -52 million EUR. Tick rows to compare them in a chart.
All figures in millions of EUR.
Tick rows to compare them in a chart (up to 4)
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -19 | -25 | -47 | -52 | |
| 0.0 | 0.1 | 0.3 | 0.2 | |
| 2.2 | 2.2 | 1.1 | 5.4 | |
| 1.4 | 4.1 | -1.3 | 0.4 | |
| 0.0 | 0.0 | 0.7 | 0.0 | |
| – | – | – | -33 | |
| -0.7 | -0.1 | -0.2 | -0.3 | |
| 38 | 79 | 97 | -0.3 | |
| -26 | 95 | 49 | -85 | |
| -19 | -25 | -48 | -52 |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.